Johnson & Johnson (JNJ) To Go Ex-Dividend on February 24th

Johnson & Johnson (NYSE:JNJ) announced a quarterly dividend on Friday, January 2nd. Stockholders of record on Tuesday, February 24th will be given a dividend of 1.30 per share on Tuesday, March 10th. This represents a c) annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, February 24th.

Johnson & Johnson has increased its dividend by an average of 0.1%annually over the last three years and has raised its dividend annually for the last 64 consecutive years. Johnson & Johnson has a dividend payout ratio of 46.8% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Johnson & Johnson to earn $11.07 per share next year, which means the company should continue to be able to cover its $5.20 annual dividend with an expected future payout ratio of 47.0%.

Johnson & Johnson Price Performance

NYSE JNJ opened at $242.27 on Friday. The company has a market cap of $583.86 billion, a PE ratio of 21.93, a P/E/G ratio of 2.35 and a beta of 0.35. The firm’s 50 day moving average price is $221.06 and its 200-day moving average price is $199.24. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $246.96.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The company had revenue of $24.28 billion during the quarter. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.